RPG Life Sciences expands API business through acquisitions

RPG Life Sciences has accelerated its expansion in the active pharmaceutical ingredient (API) segment, committing more than ₹500 crore for acquisitions, manufacturing expansion, product development and regulatory access. The company has completed two acquisitions in recent weeks, including the API and intermediates business of Raghava Life Sciences for up to ₹135 crore. The strategy is aimed at building a larger, integrated API platform through a “buy-and-build” approach. Following the acquisitions, manufacturing capacity has increased from 110 kilolitres to 505 kilolitres, while the product portfolio has expanded from 14 to 45 products. The company is also targeting greater utilisation of the acquired facilities and expansion of its third-party and export customer base. The development could strengthen RPG Life Sciences’ presence in the API market and provide opportunities for revenue growth through improved capacity utilisation, differentiated products and wider market access. However, the financial benefit will depend on successful integration, customer additions and the profitability of the acquired businesses. Investors should monitor acquisition execution, utilisation levels, additional capital requirements and regulatory progress.